Advantan ointment d / nar. approx. 0.1% tube 50g # 1
Dosage:
0.1% x 15g
0.1% x 50g
Release form:
Cream
Ointment
Emulsion
Category
Psoriasis
Scope of the medicinal product
Dermatology
Release form
Ointment
Manufacturer country
Italy
Package quantity, pcs
one
Release form, composition and packaging
Ointment for external use 0.1% white or slightly yellowish, homogeneous, opaque.
1 g
methylprednisolone aceponate 1 mg
white soft paraffin - 350 mg, liquid paraffin - 239 mg, white beeswax - 40 mg, Dehimuls E emulsifier - 70 mg, purified water - 300 mg.
15 g - aluminum tubes (1) - cardboard packs.
50 g - aluminum tubes (1) - cardboard packs.
pharmachologic effect
When applied externally, Advantan suppresses inflammatory and allergic skin reactions, as well as reactions associated with increased proliferation, which leads to a decrease in objective symptoms of inflammation (including erythema, edema, oozing, etc.) and subjective sensations (including itching, irritation, pain, etc.).
When methylprednisolone aceponate is used externally at the recommended dose, the systemic effect is minimally expressed in both humans and animals.
After repeated application of Advantan to large surfaces (40-60% of the skin surface), as well as when applied under an occlusive dressing, there are no adrenal dysfunctions: the level of cortisol in the blood plasma and its circadian rhythm remain within normal limits, the decrease in the level of cortisol in daily urine is not going on.
In the course of clinical studies with the use of Advantan for up to 12 weeks in adults and up to 4 weeks in children (including young children), the development of skin atrophy, telangiectasias, stretch marks and acne-like rashes was not revealed.
Methylprednisolone aceponate (especially its main metabolite - 6alpha-methylprednisolone-17-propionate) binds to intracellular glucocorticoid receptors.
The steroid-receptor complex binds to specific regions of the immune response cells' DNA, thus causing a series of biological effects.
In particular, the binding of the steroid-receptor complex to the DNA of cells of the immune response leads to the induction of the synthesis of macrocortin.
Macrocortin inhibits the release of arachidonic acid and thus the formation of inflammatory mediators such as prostaglandins and leukotrienes.
Inhibition of corticosteroids synthesis of vasodilating prostaglandins and potentiation of the vasoconstrictor action of adrenaline leads to a vasoconstrictor effect.
Pharmacokinetics
Suction
The degree of percutaneous absorption depends on the condition of the skin, the dosage form and the route of administration (with or without an occlusive dressing).
When using an ointment, cream or fatty ointment, percutaneous absorption in children and adults with atopic dermatitis (neurodermatitis) and psoriasis was no more than 2.5%, which is only slightly higher than in healthy volunteers (0.5-1.5%).
When using the drug in the form of an emulsion, the intensity of absorption through the skin with artificial inflammation was very low (0.27%), which is only slightly higher than through healthy skin (0.17%).
In the case of whole body treatment (eg, sunburn), the systemic dose is about 4 μg / kg bw / day, which excludes systemic effects.
Metabolism and excretion
Methylprednisolone aceponate is hydrolyzed in the epidermis and dermis.
The main and most active metabolite is 6alpha-methylprednisolone-17-propionate, which has a significantly higher affinity for glucocorticoid receptors in the skin, which indicates the presence of its bioactivation in the skin.
After entering the systemic circulation, 6alpha-methylprednisolone-17-propionate is rapidly conjugated with glucuronic acid and, thus, in the form of 6alpha-methylprednisolone-17-propionate glucuronide is inactivated.
Metabolites of methylprednisolone aceponate are eliminated mainly by the kidneys, T1 / 2 - about 16 hours.
Methylprednisolone aceponate and its metabolites do not accumulate in the body.
Indications for use
Ointment, cream, oily ointment
Inflammatory skin diseases sensitive to topical GCS therapy:
- atopic dermatitis, neurodermatitis, children's eczema
- true exe
Name ENG
ADVANTAN
Clinical and pharmacological group
GCS for external use
ATX code
Methylprednisolone aceponate
Dosage
0.1% x 50g
Structure
1 g of ointment contains: methylprednisolone aceponate 1 mg.
Excipients: white soft paraffin - 350 mg, liquid paraffin - 239 mg, white beeswax - 40 mg, emulsifier Dehimuls E - 70 mg, purified water - 300 mg.
Indications
Inflammatory skin diseases sensitive to topical GCS therapy:
atopic dermatitis, neurodermatitis, childhood eczema
true eczema
microbial eczema
professional eczema
dyshidrotic eczema
simple contact dermatitis
allergic (contact) dermatitis.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 3 years
INN / Active ingredient
methylprednisolone aceponate
Contraindications
tuberculosis of the skin and skin manifestations of syphilis in the area of application of the drug
viral skin lesions in the area of application of the drug (for example, with chickenpox, shingles)
rosacea, perioral dermatitis in the area of application of the drug
skin manifestations of a reaction to vaccination
children's age up to 4 months
hypersensitivity to drug components.
Specifications
Category
Psoriasis
Scope of the medicinal product
Dermatology
Release form
Ointment
Manufacturer country
Italy
Package quantity, pcs
one
Minimum age from
3 months
Way of introduction
On the skin
Vacation conditions
Without recipe
Brand name
Bayer
The amount of the dosage form in the primary package
50 g
Primary packaging type
Tuba
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Topical glucocorticosteroid
Anatomical and therapeutic characteristics
D07AC14 Methylprednisolone aceponate
Dosage form
Ointment for external use
Dosage (volume) of the substance in the preparation
1 g: methylprednisolone aceponate 1 mg
Expiration date in days
1095
The target audience
Children
Package weight, g
fifty
Mode of application
:
The drug is applied 1 time / day in a thin layer to the affected skin.
Continuous daily use of Advantan in the form of an ointment is for adults no more than 12 weeks, for children - no more than 4 weeks.
Information on technical characteristics, delivery set, country of manufacture